Welcome to our dedicated page for Biohaven news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven stock.
Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company whose news flow centers on progress across its immunology, obesity, neuroscience and oncology pipelines. Company updates frequently cover clinical trial readouts, regulatory interactions, financing events and scientific presentations that shape the outlook for its drug development platforms.
Investors and followers of BHVN news can expect detailed announcements on Biohaven’s Kv7 ion channel modulation programs, including opakalim in refractory focal epilepsy and major depressive disorder, as well as updates on the MoDE™ and TRAP™ extracellular degrader platforms targeting immune-mediated diseases such as IgA nephropathy and Graves’ disease. News releases also highlight the advancement of taldefgrobep alfa, a myostatin-activin pathway inhibitor in obesity and SMA, and BHV-8000, a brain-penetrant TYK2/JAK1 inhibitor in pivotal studies for early Parkinson’s disease.
Biohaven’s oncology news often focuses on early clinical data from its next-generation antibody-drug conjugates, including BHV-1510, a Trop2-directed ADC, and BHV-1530, an FGFR3-directed ADC, with reports of tumor responses, safety profiles and combination strategies with checkpoint inhibitors. Additional coverage includes regulatory milestones such as the FDA Complete Response Letter for VYGLXIA (troriluzole) in spinocerebellar ataxia and the company’s stated plans for further regulatory dialogue.
Capital markets and corporate updates—such as public offerings of common shares, at-the-market transactions, portfolio reprioritization and cost-optimization measures—also feature prominently in BHVN news. Readers who monitor this stream gain insight into Biohaven’s evolving clinical strategy, key upcoming milestones and how the company allocates resources across its late-stage programs.
Biohaven (NYSE: BHVN) received an FDA Complete Response Letter (CRL) for the NDA seeking approval of VYGLXIA (troriluzole) for spinocerebellar ataxia (SCA) on Nov 5, 2025.
Key data in the filing included a 3‑year real‑world evidence study showing a 50–70% slowing of SCA progression and a safety analysis showing >50% reduction in fall risk versus placebo, but FDA raised concerns about RWE/external control bias and study design.
Biohaven will request a meeting with FDA, continue an expanded access program, and is cutting non‑priority R&D to prioritize three late‑stage programs while targeting an ≈60% reduction in annual direct R&D spend.
Biohaven (NYSE: BHVN) reported Q2 2025 financial results and business developments, highlighting a cash position of $408.2 million as of June 30, 2025. Key developments include promising clinical results across multiple platforms: MoDE degrader BHV-1300 achieved up to 87% IgG reduction, while TRAP degrader BHV-1400 demonstrated over 80% Gd-IgA1 reductions.
The company's oncology program showed early success with BHV-1510, their Trop2 ADC, achieving tumor reduction in all initial 6 patients when combined with cemiplimab. Additionally, Biohaven initiated a pivotal Phase 2/3 study for BHV-8000 in Parkinson's disease and awaits FDA decision on VYGLXIA for spinocerebellar ataxia in Q4 2025.
Financial results showed R&D expenses of $184.4 million, down from $314.8 million in Q2 2024, with a net loss of $198.1 million ($1.94 per share) compared to $319.8 million ($3.64 per share) in the prior year.
- Tumor reduction in all 6 patients treated with BHV-1510/cemiplimab combination - Favorable safety profile with manageable toxicity - No cases of interstitial lung disease and low gastrointestinal toxicity rates
Additionally, Biohaven announced dosing of the first patient with BHV-1530, their novel FGFR3-directed ADC. This potential first-in-class treatment targets FGFR3-driven cancers, including urothelial cancers. The company is also advancing collaborations with Merus and GeneQuantum on preclinical ADC programs using their proprietary TopoIx payload technology.
The FDA has extended the PDUFA date for Biohaven's (NYSE: BHVN) troriluzole new drug application (NDA) for treating spinocerebellar ataxia (SCA) by three months to Q4 2025. The extension allows for a full review of recent submissions, and the FDA plans to hold an advisory committee meeting. No new concerns were raised.
Troriluzole, which has received Fast-Track, Orphan Drug Designation, and Priority Review from the FDA, could become the first FDA-approved treatment for SCA, a rare genetic neurodegenerative disease. Clinical data shows troriluzole, a once-daily oral pill, slows disease progression by 50-70% and reduces fall risk. The mid-cycle review revealed no major safety concerns, and a Risk Evaluation and Mitigation Strategy (REMS) appears unnecessary.
Biohaven (NYSE: BHVN) has secured a significant non-dilutive investment of up to $600 million from Oberland Capital Management The deal structure includes:
- $250 million to be funded at closing by April 30, 2025
- $150 million available upon achieving regulatory milestones for troriluzole
- Up to $200 million by mutual agreement for strategic acquisitions
The investment, structured as a Note Purchase Agreement (NPA), will support ongoing clinical trials and commercialization efforts, particularly for troriluzole in treating spinocerebellar ataxia (SCA), a rare genetic condition with no available treatments. In exchange, Oberland Capital will receive regulatory milestone payments through 2030 and tiered single-digit royalties on troriluzole global sales for up to 10 years.
Biohaven (NYSE: BHVN) announced its presentation of 13 abstracts at the 2025 American Academy of Neurology Annual Meeting in San Diego (April 5-9, 2025). The presentations include 3 oral and 10 poster presentations showcasing the company's neuroscience pipeline across multiple development programs.
The presentations focus on various therapeutic areas including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Key highlights include data on BHV-8000 for Parkinson's Disease, BHV-2100 for pain and migraine, and BHV-1310 for IgG reduction.
The company's Chief Medical Officer, Dr. Irfan Qureshi, emphasized their commitment to developing first-in-class therapies for neurological disorders with inadequate or no treatment options, anticipating critical value-creating milestones throughout 2025.
Biohaven (NYSE: BHVN) has reported positive Phase 1 data for BHV-1300, a potential first-in-class IgG1,2,4 selective degrader. The subcutaneous administration achieved up to 84% reduction in total IgG with a median reduction of 80% after weekly 1000 mg dosing.
BHV-1300 demonstrated rapid, deep, and sustained reductions in IgG levels within hours of each weekly dose. The drug was well-tolerated up to 2000 mg doses with mostly mild, self-resolving adverse events and no serious safety concerns. The treatment specifically targets IgG1,2,4 while sparing IgG3, maintaining key immune defenses.
Based on these results, Biohaven plans to initiate a Phase 2 study in Graves' disease in mid-2025. Graves' disease affects 3 million people in the US and 80 million globally. The company's MoDE™ technology allows for customization of IgG lowering across different disease indications.